NasdaqGS:INSMBiotechs
Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market
Insmed (INSM) saw a significant price move of 87% over the past quarter, driven by pivotal product developments and regulatory milestones. The FDA's approval of BRINSUPRI as the first oral treatment for non-cystic fibrosis bronchiectasis was a key highlight, potentially opening up a substantial market opportunity. Meanwhile, the designation of Maxor Specialty Pharmacy as a limited distribution provider further strengthened the product's market presence. Despite reporting a net loss for Q2...